[CAS NO. 1201902-80-8] Ixazomib Citrate (MLN9708) Analogue
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1201902-80-8]
Store
Catalog
SLK-S2181
Brand
Selleck
CAS
1201902-80-8
DESCRIPTION [1201902-80-8]
Overview
| MDL | MFCD18251437 |
|---|---|
| Molecular Weight | 517.12 |
| Molecular Formula | C20H23BCl2N2O9 |
| SMILES | O=C(C(C1)(CC(O)=O)OB([C@@H](NC(CNC(C2=CC(Cl)=CC=C2Cl)=O)=O)CC(C)C)OC1=O)O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9338 mL | 9.6689 mL | 19.3379 mL |
| 5 mM | 0.3868 mL | 1.9338 mL | 3.8676 mL |
| 10 mM | 0.1934 mL | 0.9669 mL | 1.9338 mL |
| 50 mM | 0.0387 mL | 0.1934 mL | 0.3868 mL |
Description
Ixazomib Citrate (MLN9708) Analogue is the analogue of Ixazomib Citrate (MLN9708) from WO2016165677A1. Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the with of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces . Phase 3.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.